Covert macrovascular disease and early outcome after ischemic cerebrovascular events
By
Priyanka Boettger
Linda Vollmann
Jamschid Sedighi
Hassan Hassan
Heinz Frederik Noll
Pascal Bauer
Tobias Braun
Michael Buerke
Heidrun Kraemer-Best
Martin Juenemann
Omar Alhaj Omar
Samuel Sossalla
June 8, 2026
Clinical Scorecard: Subclinical Macrovascular Pathology and Initial Outcomes Following Ischemic Stroke Events
At a Glance
Category Detail
Condition Key Mechanisms Influences cerebral perfusion, embolic propensity, and functional recovery after ischemic stroke; reflects systemic vascular vulnerability. Target Population Care Setting
Key Highlights
CMVD includes non-stenotic carotid plaques and aortic arch atheroma. Modern imaging techniques reveal high-risk features in non-culprit plaques. CMVD may reflect systemic vascular vulnerability and impact stroke prognosis. Stroke severity assessed using NIHSS; functional outcome evaluated with mRS. Study adhered to AHA/ASA standards for stroke assessment. Guideline-Based Recommendations
Diagnosis
Ischemic stroke defined by imaging-confirmed infarction or clinical syndrome. TIA defined by transient neurological symptoms without acute infarction. Management
Systematic collection of demographic data, vascular risk factors, and comorbidities at admission. Utilize advanced imaging techniques to identify CMVD. Monitoring & Follow-up
Stroke severity and functional outcomes monitored using NIHSS and mRS. Risks
Metabolic dysregulation may amplify endothelial dysfunction and vascular inflammation. Patient & Prescribing Data
Consecutive patients admitted with suspected acute stroke or TIA.
Covert macrovascular disease may influence stroke severity and functional outcomes; consider in treatment planning.
Clinical Best Practices
Use standardized diagnostic work-up for stroke classification. Employ interdisciplinary adjudication for imaging findings. Establish follow-up protocols for patients with identified CMVD. Related Resources & Content
